Preradiation Therapy PSA Is Predictive of Biochemical Progression-free Survival Following Postprostatectomy Salvage Radiation Therapy

被引：0

作者：

Shukla, M. E. ^{[1
]}

Mir, M. C. ^{[1
]}

Stephenson, A. J. ^{[1
]}

Stephans, K. L. ^{[1
]}

Klein, E. A. ^{[1
]}

Tendulkar, R. D. ^{[1
]}

机构：

[1] Cleveland Clin, Cleveland, OH 44106 USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 84卷 / 03期

关键词：

D O I：

10.1016/j.ijrobp.2012.07.1067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S404 / S404

页数：1

共 50 条

[41] Progression-free survival versus overall survival as the primary end point in anticancer drug trials: Increasingly relevant impact of therapy following progression
Maurie Markman
Current Oncology Reports, 2009, 11 : 1 - 2
[42] Progression-Free Survival Versus Overall Survival as the Primary End Point in Anticancer Drug Trials: Increasingly Relevant Impact of Therapy Following Progression
Markman, Maurie
CURRENT ONCOLOGY REPORTS, 2009, 11 (01) : 1 - 2
[43] Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy:: A longitudinal study of protein kinetics throughout tumor progression and therapy
Chan, LW
Moses, MA
Goley, E
Sproull, M
Muanza, T
Coleman, CN
Figg, WD
Albert, PS
Ménard, C
Camphausen, K
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) : 499 - 506
[44] Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
Soria, J. C.
Massard, C.
Le Chevalier, T.
ANNALS OF ONCOLOGY, 2010, 21 (12) : 2324 - 2332
[45] Stereotactic Ablative Radiation Therapy Improves Progression-free Survival and Local Control In Patients with Oligometastatic Lung Cancer
Blake, M.
Maldonado, F.
De la Mata, D.
Gerson, R.
Flores, F.
Barron, F.
Butler, E. B.
Teh, B. S.
Pino, R.
Hernandez-Bojorquez, M.
Corona, F.
Flores, D.
Arrieta, O.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E675 - E675
[46] Maintenance therapy in advanced ovarian cancer: Progression-free survival and clinical benefit
Ozols, RF
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) : 2451 - 2453
[47] Therapy of recurrent and refractory multiple Myeloma Isatuximab improves progression-free Survival
Ruedesheim, Sabine M.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (7-8) : 397 - 397
[48] Longer progression-free survival with targeted therapy for patients with metastatic breast cancer
Nierengarten, Mary Beth
CANCER, 2025, 131 (07)
[49] Predictors of biochemical relapse following salvage radiation therapy for recurrent prostate cancer
Parker, AS
Buskirk, S
Heckman, MG
Pisansky, T
Prussak, KA
Welde, M
Ferrigni, RG
Schild, SE
Myers, RP
JOURNAL OF UROLOGY, 2005, 173 (04): : 129 - 129
[50] MRI Biomarkers of Bevacizumab Therapy Correlate with Progression-Free Survival but Not Overall Survival in Recurrent Glioblastoma
Dillon, William P.
RADIOLOGY, 2020, 297 (01) : 176 - 177

← 1 2 3 4 5 →